HPCAL1 and hepatocellular carcinoma: However, MG-132 (a proteasome inhibitor) did not significantly change the expression level of VILIP3 in the desloratadine-treated HCC cells, indicating that the VILIP3 protein may not be degraded via the ubiquitin-proteasome system (Fig. 5d).